IpY.20 / Concarlo - LARVOL DELTA

IpY.20: Innovative strategies for post-CDK estrogen receptor (ER)+ metastatic breast cancer (mBC) (AACR 2024) - "Approval of CDK 4/6i such as palbociclib, though a game changer for ER+ mBC, resulted in tumor resistance, leaving patients without effective treatments and a 5-yr survival of only 30%. These findings underscore the significance of coordinated targeting of CDK2/4/6, making IpY.20 a first-in-class product uniquely exploiting p27-mediated CDK2/4/6 regulation. Direct targeting of p27 presents a new treatment paradigm bypassing the challenges of ATP-competitive CDKis, with potential to expand into tumor types with aberrant p27, CDK2/4/6 activity, or RAS/MAPK pathways that increase CDK4/6 activity."

Late-breaking abstract • Metastases • Breast Cancer • Eye Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Retinoblastoma • Solid Tumor • CCL20 • CCND1 • CDKN2A • ER • HER-2

IpY.20, a first-in-class inhibitor of p27Kip1, inhibits CDK4/6 and CDK2 to kill tumor cells (AACR 2023) - "The drug resistance seen in the presence of CDK4/6 inhibitors, such as palbociclib, can be attributed to compensatory activation of tumor cell proliferation by CDK2. In vivo, IpY.20 reduces tumor volume and increases OS in cell line-derived xenografts (CDX).IpY.20 has several important differentiating features when compared to CDK4/6 or CDK2 inhibitors: targeting p27 is more selective with fewer off-target effects than the ATP-competitive small molecule CDK4/6i currently in use; IpY.20 induces tumor cell death as opposed to cytostasis; the specific form of tumor cell death that is induced upon IpY.20 treatment, i.e., necroptosis, stimulates the innate and adaptive immune system.As the bulk of drug resistance seen with CDK or RAS/MAPK pathway targeting drugs is a result of compensatory CDK2 activity, IpY.20 will be a valuable member of the clinical arsenal for patients with drug resistant tumors. Currently, a robust clinical manufacturing process has been completed for..."

Tumor cell • Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • CDK4